MRCY · Mercury Systems

The thesis

Mercury Systems beat forecasts for its fiscal first quarter of 2027 and raised its full-year profit and cash outlook on 10 November 2026. That makes the shares modestly more likely than not to beat the S&P 500 over the next three months. The case now rests on margins and cash, and the fiscal second-quarter report, expected in early February 2027, shows whether the raised targets hold.

In the quarter to 2 October 2026, revenue was about $253 million, up 12.4% year over year. Adjusted earnings were $0.52 per share, against $0.26 a year earlier (company 8-K, 10 November 2026). News reports on 10 November 2026 put the consensus at $0.30 per share on $244.9 million of revenue. Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $56 million, a 22.3% margin.

Management raised its fiscal 2027 adjusted EBITDA outlook to about $210 million, from approaching $200 million. It raised its free cash flow conversion target to approaching 40%, from approaching 35% (earnings presentation, 10 November 2026). On 11 November 2026, JPMorgan upgraded the shares to Overweight with a $102 target, and Piper Sandler reiterated Overweight with a $107 target.

The price already reflects part of the beat. The shares closed at $88.33 on 11 November 2026, up from $79.62 on 9 November 2026, the session before the report. They remain 31.2% below the 52-week intraday high of $128.45 set on 6 July 2026. The rating is Medium because the profit and cash guidance rose on a dated report while the shares still trade below their 200-day moving average.

Bullish and bearish views on Mercury Systems Inc

The bull case on Mercury Systems Inc (MRCY), in brief: orders keep outrunning revenue. The bear case: cash still flowed out in the quarter.

Bull case

• Orders keep outrunning revenue. First-quarter bookings were $370 million, up 48.0% year over year, for a book-to-bill ratio (orders divided by revenue) of 1.46. Backlog reached $2,061.4 million on 2 October 2026, up 45% from $1,424.5 million, and backlog due within 12 months was $1,042.9 million against $815.6 million (earnings presentation, 10 November 2026).
• Margins moved sharply higher. Adjusted EBITDA rose 58.6% year over year to a 22.3% margin, which the company attributed to favorable mix (10 November 2026). The fourth quarter of fiscal 2026 margin was 16.7%, per the 18 August 2026 results.
• Profit and cash targets went up. The fiscal 2027 adjusted EBITDA target rose to about $210 million and the cash conversion target to approaching 40% (10 November 2026). Revenue growth is now described as double-digit, with total revenue still approaching $1.1 billion.
• The second quarter is guided higher. Management guided fiscal second-quarter revenue up about 10% year over year, adjusted EBITDA margin up about 500 basis points and positive free cash flow (earnings presentation, 10 November 2026).
• Accounting profit returned. First-quarter net income under generally accepted accounting principles (GAAP) was $13 million, or $0.21 per share, against a $13 million loss a year earlier. Net debt fell 19% year over year to $232 million (8-K, 10 November 2026).
• Analysts turned more positive after the report. JPMorgan upgraded to Overweight with a $102 target and Piper Sandler kept Overweight with a $107 target, both on 11 November 2026.

Bear case

• Cash still flowed out in the quarter. Operating cash flow was negative $14 million and free cash flow negative $24 million (8-K, 10 November 2026). The full-year cash target depends on a second half that management expects to exceed the first.
• The revenue target did not rise in dollars. Total fiscal 2027 revenue stays at approaching $1.1 billion (10 November 2026), against a consensus of $1.087 billion cited in news reports the same day.
• Federal funding remains on a stopgap. The continuing resolution signed on 2 September 2026 funds the Pentagon through 11 December 2026 and bars new production starts or rate increases above fiscal 2026 levels (GovConWire). Another extension would prolong award delays for defense suppliers.
• The shares sit below their long-run trend. The 11 November 2026 close of $88.33 is under the 200-day moving average of $90.72, and the three-month change is −19.5%.
• Three customers drive a third of revenue. RTX (15%), Lockheed Martin (11%) and Northrop Grumman (10%) accounted for fiscal 2026 revenue shares as shown, per the fiscal 2026 10-K, so program timing at any one of them moves a quarter.

Price setup

The shares fell to a 52-week closing low of $65.55 on 5 November 2026, then closed at $73.55 on 6 November 2026, $79.62 on 9 November 2026 and $83.58 on 10 November 2026. The first session after the report closed at $88.33 on 11 November 2026. The three-month change is −19.5%, measured from a close of $109.79 on 13 August 2026.

As of 11 November 2026, the 50-day moving average is $80.22 and the 200-day moving average is $90.72. The shares sit between the two. A move back above the 200-day average would put them over their long-run trend for the first time since the summer decline. The 9 November 2026 pre-report close and the 50-day average mark where the post-report gain would be undone. Both post-report analyst targets, JPMorgan's $102 and Piper Sandler's $107, sit below the 13 August 2026 close and well below the 52-week intraday high of $128.45 from 6 July 2026.

SEC Form 4 filings dated 29 October 2026 and 30 October 2026 show eight directors each receiving a grant of 2,348 shares on 28 October 2026. These are routine board awards, and none of the filings shows an open-market purchase or sale.

Catalysts ahead

• 11 December 2026: Expiry of the federal stopgap funding resolution. A full-year appropriation would lift the ban on new defense production starts; another stopgap would extend award delays for suppliers such as Mercury.
• ~3 February 2027 (est.): Fiscal Q2 2027 results. Tests the guidance for about 10% revenue growth, roughly 500 basis points of margin expansion and positive free cash flow that supports the raised full-year targets.

What would change the view

A daily close below $78.50, under the 50-day moving average and the 9 November 2026 close before the fiscal first-quarter report, which would erase the post-report gain; or negative free cash flow in the fiscal second-quarter 2027 report, against guidance for positive cash flow.

The risks this note tracks, each with what would confirm it:

• Cash conversion lags the raised full-year target of approaching 40%. Confirmed by: negative free cash flow in the fiscal Q2 2027 report, against guidance for positive cash flow.
• The first-quarter margin, helped by favorable mix, does not carry through the year. Confirmed by: a fiscal Q2 2027 adjusted EBITDA margin that expands by less than the roughly 500 basis points guided, or a cut to the about $210 million EBITDA target.
• Delays in defense appropriations push back new awards and revenue timing. Confirmed by: the 11 December 2026 stopgap rolling into another continuing resolution or a shutdown, or management citing award delays at the fiscal Q2 report.
• Program timing at the top three prime contractors concentrates quarterly volatility. Confirmed by: a revenue or bookings shortfall that management attributes to RTX, Lockheed Martin or Northrop Grumman program timing.

What it trades with

Mercury sells embedded processing and subsystems to prime contractors, so its orders and revenue timing follow defense program schedules at RTX, Lockheed Martin and Northrop Grumman. Federal appropriations timing, including the 11 December 2026 stopgap expiry, affects the whole group of defense electronics suppliers at once. Over the past three months the shares have moved mainly on the company's own backlog, margin and cash-flow debate. The 10 November 2026 report and the 11 November 2026 upgrade drove the latest move more than anything in the wider defense group.